177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)

Purpose Preliminary data from retrospective analyses and recent data from large randomized controlled trials suggest safety and efficacy of radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC). Limited data...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of nuclear medicine and molecular imaging Vol. 49; no. 3; pp. 1075 - 1085
Main Authors:	Khreish, Fadi, Ghazal, Zaidoon, Marlowe, Robert J., Rosar, Florian, Sabet, Amir, Maus, Stephan, Linxweiler, Johannes, Bartholomä, Mark, Ezziddin, Samer
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01-02-2022 Springer Nature B.V
Subjects:	Aged Anemia Antigens Cardiology Castration Clinical trials Confidence intervals Data analysis Dipeptides - adverse effects Disease control Heterocyclic Compounds, 1-Ring - adverse effects Humans Imaging Lutetium Lutetium - therapeutic use Lutetium isotopes Lymphopenia Male Median (statistics) Medicine Medicine & Public Health Metastases Metastasis Nuclear Medicine Oncology Original Original Article Orthopedics Patients Prospective Studies Prostate cancer Prostate-Specific Antigen Prostatic Neoplasms, Castration-Resistant - pathology Prostatic Neoplasms, Castration-Resistant - radiotherapy Radioisotopes Radiology Registries Retrospective Studies Safety Statistical methods Survival Therapy Thrombocytopenia Treatment Outcome Xerostomia Prostate-specific membrane antigen (PSMA) Everyday practice Lutetium-177-PSMA-617 radioligand therapy Metastatic castration-resistant prostate cancer (mCRPC) “Real-world” data LuPSMA-617 RLT Lutetium-177-PSMA-617 radioligand therapy (177LuPSMA-617 RLT)
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!